指南与共识泌尿男性生殖肿瘤

立体定向体部放疗治疗原发性肾细胞癌:国际立体定向放射外科学会(ISRS)的系统综述与实践指南

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
指南 / 共识 · Lancet Oncol · 2024-01-01

该系统综述由国际立体定向放射外科学会(ISRS)开展,筛选3972篇文献纳入36项研究共822例患者,评估立体定向体部放疗(SBRT)治疗原发性肾细胞癌的安全性和有效性,并据此制定实践指南,回答剂量分割、治疗后活检、孤立肾应用及随访四个关键临床问题。

要点

  • 中位局部控制率为94.1%(范围70.0-100),5年无进展生存率为80.5%(95%CI 72-92),5年总生存率为77.2%(95%CI 65-89)。
  • 最佳剂量分割为单次25-26 Gy,或较大肿瘤分3次42-48 Gy。
  • 不推荐常规治疗后活检,因其不能预测患者结局;孤立肾患者行SBRT安全有效。

核心结论

  • 该系统综述与实践指南支持将SBRT作为原发性肾细胞癌安全有效的标准治疗选择。
  • 需要与手术及侵入性消融治疗进行随机对照试验以进一步明确最佳实践。

研究设计与样本

  • 国际立体定向放射外科学会(ISRS)开展的系统综述与实践指南,筛选3972篇文献,纳入36项研究共822例患者。

主要发现

  • 中位局部控制率为94.1%(范围70.0-100)。
  • 5年无进展生存率为80.5%(95%CI 72-92)。
  • 5年总生存率为77.2%(95%CI 65-89)。

关键数值与推荐

  • 最佳剂量分割为单次25-26 Gy,或较大肿瘤分3次42-48 Gy。
  • 不推荐常规治疗后活检,因其不能预测患者结局。
  • 孤立肾原发性肾细胞癌行SBRT安全有效。
  • 治疗后随访包括腹部横断面成像(含双肾、肾上腺)及胸部监测,初始每6个月一次。

临床怎么用

  • SBRT可作为医学上无法手术、技术高风险或拒绝手术的原发性肾细胞癌患者的一种新选择。
  • 治疗后随访建议包括腹部横断面成像(含双肾、肾上腺)及胸部监测,初始每6个月一次。

局限性

  • 需要与手术及侵入性消融治疗进行随机对照试验以进一步明确最佳实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surgery is the standard of care for patients with primary renal cell carcinoma. Stereotactic body radiotherapy (SBRT) is a novel alternative for patients who are medically inoperable, technically high risk, or who decline surgery. Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted prospective clinical trials. This systematic review was performed to assess the safety and efficacy of SBRT for primary renal cell carcinoma. Review results then formed the basis for the practice guidelines described, on behalf of the International Stereotactic Radiosurgery Society. 3972 publications were screened and 36 studies (822 patients) were included in the analysis. Median local control rate was 94·1% (range 70·0-100), 5-year progression-free survival was 80·5% (95% CI 72-92), and 5-year overall survival was 77·2% (95% CI 65-89). These practice guidelines addressed four key clinical questions. First, the optimal dose fractionation was 25-26 Gy in one fraction, or 42-48 Gy in three fractions for larger tumours. Second, routine post-treatment biopsy is not recommended as it is not predictive of patient outcome. Third, SBRT for primary renal cell carcinoma in a solitary kidney is safe and effective. Finally, guidelines for post-treatment follow-up are described, which include cross-axial imaging of the abdomen including both kidneys, adrenals, and surveillance of the chest initially every 6 months. This systematic review and practice guideline support the practice of SBRT for primary renal cell carcinoma as a safe and effective standard treatment option. Randomised trials with surgery and invasive ablative therapies are needed to further define best practice.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Siva S, Louie AV, Kotecha R, et al. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol. 2024. PMID: 38181809. doi:10.1016/S1470-2045(23)00513-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。